6.2.3: Case Study - The Phase III Cliff

Auris Therapeutics: Eighty Percent on One Number

CFO Miriam Cole laid the numbers out plainly for the Portfolio Review Board. Auris Therapeutics had 360 million dollars in development capital to work with over the next three years, and the pivotal Phase III program for AT-501, the company's most promising asset, was going to cost 285 million dollars of it. CardioVasc, the anticoagulant funding nearly all of Auris's revenue, had four years left on its patent before generics wiped out most of its pricing power, and AT-501 was the only asset in the pipeline with a credible shot at replacing it. "There's no version of this where we fund AT-501 at full strength and keep the rest of the pipeline moving at the same pace," Miriam said. "We can partner AT-501 out and free up cash for everything else, or we can fund it alone and starve the rest of the portfolio to do it."

Grace Talbot, who ran corporate development, pushed hard for the partnership. "A global pharma partner would cover somewhere between sixty and a hundred percent of the Phase III cost," she said. "We'd give up forty percent of the downstream margin if it succeeds, but we'd keep AT-304 and AT-109 alive, and if AT-501 fails, we're not the ones holding all the risk." CEO Daniel Kessler wasn't interested. "We built this pathway ourselves," he said. "I'm not handing forty percent of a potential billion-dollar drug to a partner because we're afraid of our own trial." Chief Scientific Officer Dr. Elias Novak backed him without hesitation. "The biomarker data from Phase IIb is some of the strongest I've seen in a decade of respiratory work," he said. "This isn't a coin flip. Partnering here means giving away margin on a drug we already believe in." The board voted with Kessler and Novak. AT-304's trial expansion went on operational hold, freezing forty-five million dollars in near-term spending. AT-109's Phase I enrollment slowed by 70 percent. Discovery chemistry got cut down to maintenance funding. Auris had turned itself, in a single meeting, into a company betting its future on one asset.

Twenty-eight months later, Program Director Sofia Ibarra walked the board through a status update that looked, by every operational measure, like a model program. Patient enrollment across the AURA-1 and AURA-2 trials had finished six weeks ahead of schedule, dropout rates sat at 3.2 percent against an industry average north of 10, and FDA site audits had come back clean. Cost and schedule performance indices both ran comfortably above 1.0. "This is as clean an execution as I've run in this role," Sofia said, and nobody in the room disagreed with her. Grace, still the one voice that hadn't fully relaxed, raised something anyway. "None of that tells us whether the drug actually works," she said. "Phase III failure rates for novel asthma biologics run forty-five to fifty percent industry-wide, and everything we're celebrating today is about how well we ran the trial, not about whether the biology holds up." Novak waved it off gently. "The biomarkers are strong, Grace," he said. "We've been over this." The meeting moved on.

The unblinded data came back on a Friday morning in October of Year 3, and it ended the argument in a way nobody in that earlier meeting had wanted to be right about. AT-501 produced an 8 percent reduction in asthma exacerbation rates against placebo, far short of the 25 percent the trial had been powered to detect, with a p-value of 0.18 against the 0.05 threshold needed for significance. A narrow subgroup with high baseline eosinophil counts showed a 14 percent improvement, but the sample was too small to support a regulatory filing on its own. Worse, patients in the high-dose arm showed a statistically significant rise in liver enzymes, a safety signal that closed off any path to an accelerated approval built around the subgroup result. Elias Novak read the report twice before saying anything. "The mechanism was sound," he said quietly. "I still believe the mechanism was sound." Daniel Kessler didn't respond to that. He was already looking at what came next.

What came next arrived fast. Monday morning's market open erased 1.8 billion dollars in shareholder value within three hours as the stock dropped 74 percent. When the board turned to the rest of the pipeline for anything to point to instead, there was almost nothing there. AT-304 was still two years from a Phase II readout because its funding had been frozen to pay for AT-501. AT-109 was still deep in Phase I safety work. CardioVasc's patent cliff was now eighteen months away, and the company had 48 million dollars in liquid cash left against a 285 million dollar bet that hadn't paid off. Miriam Cole put the number in front of the board without softening it. "Forty-eight million doesn't fund the rest of the pipeline and it doesn't fund an acquisition," she said. "It funds maybe two quarters of runway while we figure out what we actually are now."

Grace Talbot didn't say "I told you so" out loud, but she didn't have to. Someone else on the board said it for her. "If we'd taken the partnership Grace proposed two years ago," a director said, "we'd have kept a hundred and seventy million dollars in reserve, AT-304 would be finishing Phase IIb right now instead of sitting frozen, and we wouldn't be looking at forty-eight million dollars and a patent cliff eighteen months out." Daniel Kessler didn't have an answer ready. Neither did Novak, who was still turning over biomarker data from a drug that no longer had a regulatory pathway in front of it. A multinational competitor had already made an informal approach about acquiring Auris outright, at a steep discount to where the company had traded before Friday's readout, mostly interested in harvesting whatever cash flow CardioVasc had left before its patent expired. The board hadn't decided whether to engage with that offer or try to survive independently on 48 million dollars and a frozen pipeline, and nobody in the room, including Kessler, seemed to know which answer they were actually going to give.

Discussion Questions

This section is designed for you to pause and consider how these leadership concepts land in your own professional world. There are no right or wrong answers here. Instead, these questions are meant to help you audit your current approach and identify where you might want to pivot.

1. Daniel Kessler and Elias Novak rejected Grace Talbot's partnership proposal because they believed in AT-501's science and didn't want to surrender margin on a drug they were confident would succeed. How should a portfolio manager establish a non-negotiable capital concentration limit in an organization where leadership is this personally and professionally invested in a single program's success?
2. Sofia Ibarra's execution metrics, schedule, dropout rate, audit results, CPI, and SPI, were all excellent right up until the unblinded readout failed. Why did none of those metrics give the board any early warning of the actual risk, and what would Grace have needed to track instead to keep the biological failure probability visible in the room alongside the operational dashboard?
3. Grace's original proposal would have had a partner cover sixty to a hundred percent of the Phase III cost in exchange for forty percent of the downstream margin. Given what actually happened to Auris, was that trade genuinely favorable, or would you have wanted different terms before recommending the board accept it?